Revolutionizing Gene Therapy Delivery to the Retina
Returning in September as a digital event, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.
Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics, Biogen, Gyroscope Therapeutics, Novartis, Horama and REGENXBIO
Join 150+ fellow industry attendees from discovery, preclinical and clinical backgrounds, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders.
Access the official agenda for more information.
Previous Gene Therapy for Ophthalmic Disorders Attendees Have Said:
“Very efficiently organized, excellent speakers.”
Chief Executive Officer - Eyevensys
“Very well organized and informative virtual conference!”
Senior Director, Regulatory Affairs - Adverum
“Well thought agenda covering key hot
topics with great participation.”
Vice President, Preclinical Development - Clearside Biomedical
What Will You Learn?
The latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation
How Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures
Optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight
Clinical progress with different administration routes to the eye with clinical experience from REGENXBIO
Key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing
The realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics